Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B-cell cytotoxicity in chronic lymphocytic leukemia.
about
The emerging role of FTY720 (Fingolimod) in cancer treatmentPulmonary Toxicities of Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis of Randomized Controlled TrialsRole of Tyrosine Kinase Inhibitors in Indolent and Other Mature B-Cell NeoplasmsPre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1Switching the sphingolipid rheostat in the treatment of diabetes and cancer comorbidity from a problem to an advantage.A systematic evaluation of the safety and toxicity of fingolimod for its potential use in the treatment of acute myeloid leukaemia.Use of a Novel Integrase-Deficient Lentivirus for Targeted Anti-Cancer Therapy With Survivin Promoter-Driven Diphtheria Toxin ADisruption and inactivation of the PP2A complex promotes the proliferation and angiogenesis of hemangioma endothelial cells through activating AKT and ERK.Human umbilical cord-derived mesenchymal stem cells protect against experimental colitis via CD5(+) B regulatory cellsThe antineoplastic properties of FTY720: evidence for the repurposing of fingolimod.Decreased WNT3 expression in chronic lymphocytic leukaemia is a hallmark of disease progression and identifies patients with worse prognosis in the subgroup with mutated IGHV.Non-immunosuppressive FTY720-derivative OSU-2S mediates reactive oxygen species-mediated cytotoxicity in canine B-cell lymphoma.Therapeutic Targeting of PP2A.Maintenance and pharmacologic targeting of ROR1 protein levels via UHRF1 in t(1;19) pre-B-ALL.
P2860
Q26748927-12D5DFA8-7143-4506-B85C-354406ED8BE8Q26768125-FB1C04FE-C2C1-4FCA-AA07-8D7BFD0C31C2Q26795594-A5812D18-5845-4058-AB05-45D07DAFDD38Q26795679-3B6ED3A5-882B-4664-9D4F-16A24FB10A6CQ35249824-7FA3E3E5-103B-437A-96D5-A018B0CA5737Q35953902-F60BF77D-B582-46BD-8407-32253A45F363Q36194681-BD6103B7-F14D-40BE-BD02-5DBC07BD727CQ36413256-177C7A6B-91B1-4E9B-B59D-128CEF1E6C1BQ37169313-CB2CC6D3-6FB0-4A68-97F7-48F471ED234EQ38546700-DE6686F9-5FE6-42AC-ACDB-6A10E75A48E4Q38744622-410310E2-C479-4218-ADD2-5DE77B482550Q46554788-CB5949E5-3386-430E-8FCE-6A611ACA62D0Q47436859-64D34B00-A02D-482D-9AF6-D4BF23FC506AQ54977612-CD29DB45-F690-467F-B488-A6E89C2E45B7
P2860
Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B-cell cytotoxicity in chronic lymphocytic leukemia.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Tumor antigen ROR1 targeted dr ...... chronic lymphocytic leukemia.
@ast
Tumor antigen ROR1 targeted dr ...... chronic lymphocytic leukemia.
@en
Tumor antigen ROR1 targeted dr ...... chronic lymphocytic leukemia.
@nl
type
label
Tumor antigen ROR1 targeted dr ...... chronic lymphocytic leukemia.
@ast
Tumor antigen ROR1 targeted dr ...... chronic lymphocytic leukemia.
@en
Tumor antigen ROR1 targeted dr ...... chronic lymphocytic leukemia.
@nl
prefLabel
Tumor antigen ROR1 targeted dr ...... chronic lymphocytic leukemia.
@ast
Tumor antigen ROR1 targeted dr ...... chronic lymphocytic leukemia.
@en
Tumor antigen ROR1 targeted dr ...... chronic lymphocytic leukemia.
@nl
P2093
P2860
P921
P356
P1433
P1476
Tumor antigen ROR1 targeted dr ...... chronic lymphocytic leukemia.
@en
P2093
F W Frissora
L Andritsos
P2860
P2888
P304
P356
10.1038/LEU.2014.199
P577
2014-06-20T00:00:00Z
P5875
P6179
1037401326